Standout Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective ... 2007 2026 2013 2019 524
  1. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007)
    Hagop M. Kantarjian, Francis J. Giles et al. Blood

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 69 standout
Sub-graph 1 of 22

Citing Papers

Self-Driving Laboratories for Chemistry and Materials Science
2024 Standout
Metastasis
2023 Standout
2 intermediate papers

Works of Aaron Weitzman being referenced

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).
2013 Nobel
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
2007 Standout

Author Peers

Author Last Decade Papers Cites
Aaron Weitzman 319 557 670 414 37 1.2k
William Mietlowski 495 677 835 445 32 1.7k
Iryna Dyagil 269 687 719 317 55 1.3k
P. Berthaud 398 302 454 222 41 1.3k
Sara Redaelli 253 352 489 205 38 1.2k
Anne Blackwood‐Chirchir 465 356 399 103 22 999
Steven Novick 423 350 625 145 28 1.4k
Prasheen Agarwal 98 499 942 1003 27 1.6k
H Kantarjian 306 500 589 113 28 1.2k
Nisha Nanda 232 210 440 119 33 1.3k
Shihong Sheng 179 164 645 721 27 1.4k

All Works

Loading papers...

Rankless by CCL
2026